Sayin Aslihan, Cosar Behçet
Department of Psychiatry, Gazi University Medical School, Turkey.
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jul;30(5):958-9. doi: 10.1016/j.pnpbp.2005.11.032. Epub 2006 Apr 24.
Clozapine is a well-known antipsychotic to cause fatal agranulocytosis but there are only a few case reports about the risk of leukopenia and agranulocytosis associated with other atypical antipsychotics. Olanzapine has structural pharmacological similarities to those of clozapine and reports about haematological adverse effects of olanzapine include three groups: the first group includes cases of olanzapine-induced neutropenia, the second informing that olanzapine is safe after clozapine induced agranulocytosis and the third group forms prolongation of clozapine-induced leukopenia with olanzapine use. The aim of this paper is to report a case of prolongation of clozapine-induced leukopenia despite olanzapine treatment and discuss leukopenia caused by atypical antipsychotic use in the light of recent and limited literature.
氯氮平是一种众所周知的可导致致命性粒细胞缺乏症的抗精神病药物，但关于其他非典型抗精神病药物相关的白细胞减少症和粒细胞缺乏症风险的病例报告却很少。奥氮平在结构药理学上与氯氮平相似，关于奥氮平血液学不良反应的报告包括三类：第一类包括奥氮平诱导的中性粒细胞减少症病例；第二类表明在氯氮平诱导的粒细胞缺乏症后奥氮平是安全的；第三类是使用奥氮平使氯氮平诱导的白细胞减少症延长。本文的目的是报告一例尽管使用了奥氮平治疗但氯氮平诱导的白细胞减少症仍延长的病例，并根据近期有限的文献讨论非典型抗精神病药物使用引起的白细胞减少症。
